CHRS – coherus biosciences, inc. (US:NASDAQ)
Stock Stats
News
Yahoo Finance [Yahoo! Finance]
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 [Yahoo! Finance]
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
Neutrolis Expands Senior Leadership Team to Drive Development of Growing Pipeline of Non-Immunosuppressive Therapies for NET-mediated Autoimmune Diseases [Yahoo! Finance]
Coherus BioSciences, Inc. (NASDAQ: CHRS) had its price target raised by analysts at Robert W. Baird from $4.00 to $6.00. They now have an "outperform" rating on the stock.
Form 4 Coherus BioSciences, For: Dec 13 Filed by: Reider Paul
Form 8-K Coherus BioSciences, For: Nov 27
Form DEFA14A Coherus BioSciences,
Form DEFA14A Coherus BioSciences,
Form DEFA14A Coherus BioSciences,
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.